190 related articles for article (PubMed ID: 38003476)
1. Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis.
Kerkour T; Zhou C; Hollestein L; Mooyaart A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003476
[TBL] [Abstract][Full Text] [Related]
2. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
3. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
5. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
6. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
7.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
8. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
11. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
12. Concordance of somatic mutational profile in multiple primary melanomas.
Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
[TBL] [Abstract][Full Text] [Related]
13. Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and meta-analysis.
Zanna I; Caini S; Raimondi S; Saieva C; Masala G; Massi D; Cocorocchio E; Queirolo P; Stanganelli I; Gandini S
Mol Carcinog; 2021 Mar; 60(3):167-171. PubMed ID: 33444485
[TBL] [Abstract][Full Text] [Related]
14. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
16. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD
Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409
[TBL] [Abstract][Full Text] [Related]
18. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
20. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
